---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030219"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T01:03:00.650145+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock

## Summary
- Primary endpoint met: istaroxime significantly improved systolic blood pressure (SBP AUC) vs placebo (p=0.0070) in combined Part A/B analysis.
- Istaroxime improved cardiac output by ~15%, reduced heart rate, and lowered pulmonary capillary wedge pressure (PCWP) vs placebo at multiple timepoints.
- Renal function (eGFR) improved with istaroxime at 48 hours (p=0.0291); NYHA heart failure classification improved through 72 hours.
- Serious adverse events were similar: 10.5% istaroxime vs 27.3% placebo; no increase in clinically significant arrythmias observed.

## SEC filing metadata
- accession: 0001437749-24-030219
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774924030219/0001437749-24-030219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774924030219/wint20240929_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030219
- JSON: https://secwatch.observer/filing/0001437749-24-030219.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.